WO2021247715A3 - Immunogenic francisella antigens and their use in immunization of fish against francisellosis - Google Patents

Immunogenic francisella antigens and their use in immunization of fish against francisellosis Download PDF

Info

Publication number
WO2021247715A3
WO2021247715A3 PCT/US2021/035461 US2021035461W WO2021247715A3 WO 2021247715 A3 WO2021247715 A3 WO 2021247715A3 US 2021035461 W US2021035461 W US 2021035461W WO 2021247715 A3 WO2021247715 A3 WO 2021247715A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic
francisella
orientalis
immunization
iglc
Prior art date
Application number
PCT/US2021/035461
Other languages
French (fr)
Other versions
WO2021247715A2 (en
Inventor
Matt ROGGE
Esteban SOTO MARTINEZ
Benjamin LAFRENTZ
Khalid SHAHIN
Roshan Shrestha
Alvin CAMUS
Original Assignee
The Regents Of The University Of California
The United States Of America As Represented By The Secretary Of Agriculture
Wisys Technology Foundation, Inc.
Qualicum Labs Ltd.
University Of Georgia Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, The United States Of America As Represented By The Secretary Of Agriculture, Wisys Technology Foundation, Inc., Qualicum Labs Ltd., University Of Georgia Research Foundation, Inc. filed Critical The Regents Of The University Of California
Publication of WO2021247715A2 publication Critical patent/WO2021247715A2/en
Publication of WO2021247715A3 publication Critical patent/WO2021247715A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Immunogenic compositions that elicit immune responses against Francisella orientalis antigens are provided. In particular, immunogenic compositions comprising Francisella orientalis IglC and/or GroEL immunogenic polypeptides and/or recombinant polynucleotides encoding the Francisella orientalis IglC and/or GroEL immunogenic polypeptides, and/or microalgae expressing the Francisella orientalis IglC and/or GroEL immunogenic polypeptides are provided. Immunogenic compositions may further comprise other Francisella orientalis immunogenic polypeptides and/or immunogenic polypeptides from other pathogens causing disease in fish. The immunogenic compositions may also include one or more adjuvants. Additionally, methods of using the immunogenic compositions in applications including immunization and vaccination are provided.
PCT/US2021/035461 2020-06-03 2021-06-02 Immunogenic francisella antigens and their use in immunization of fish against francisellosis WO2021247715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063034286P 2020-06-03 2020-06-03
US63/034,286 2020-06-03

Publications (2)

Publication Number Publication Date
WO2021247715A2 WO2021247715A2 (en) 2021-12-09
WO2021247715A3 true WO2021247715A3 (en) 2022-01-13

Family

ID=78831709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/035461 WO2021247715A2 (en) 2020-06-03 2021-06-02 Immunogenic francisella antigens and their use in immunization of fish against francisellosis

Country Status (1)

Country Link
WO (1) WO2021247715A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109852588B (en) * 2018-12-24 2023-03-07 中国水产科学研究院珠江水产研究所 Monoclonal antibody of anti-tilapia immune globulin IgM, cell strain and application thereof
WO2023201119A1 (en) * 2022-04-15 2023-10-19 University Of Florida Research Foundation, Incorporated Corn phytoglycogen formulations for stabilizing proteins
CN116555346B (en) * 2023-07-05 2023-09-01 中山大学 Method for promoting growth of grass carp by adopting carbon nanotube gene carrier delivery system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162391A1 (en) * 2007-12-19 2009-06-25 Schering-Plough Animal Health Corporation Vaccine antigens from piscirickettsia salmonis
US20170128567A1 (en) * 2015-11-07 2017-05-11 Purdue Research Foundation Vaccine Adjuvants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162391A1 (en) * 2007-12-19 2009-06-25 Schering-Plough Animal Health Corporation Vaccine antigens from piscirickettsia salmonis
US20170128567A1 (en) * 2015-11-07 2017-05-11 Purdue Research Foundation Vaccine Adjuvants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE uniprot 5 October 2010 (2010-10-05), XP055894582, retrieved from ttps://www.uniprot.org/uniprot/D9IQI9 Database accession no. D9IQI9 *
SHAHIN ET AL.: "Characterisation of the outer membrane proteome of Francisella noatunensis subsp. Orientalis", JOURNAL OF APPLIED MICROBIOLOGY, vol. 125, no. 3, September 2018 (2018-09-01), pages 686 - 699, XP055894580 *

Also Published As

Publication number Publication date
WO2021247715A2 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
WO2021247715A3 (en) Immunogenic francisella antigens and their use in immunization of fish against francisellosis
US20210268092A1 (en) Subunit vaccine delivery platform for robust humoral and cellular immune responses
Baumann et al. Progress in tuberculosis vaccine development
WO2021019102A3 (en) A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes
IL138798A0 (en) Vaccines and antibodies against bacterial pneumococcal infection
US20190105350A1 (en) Vaccine compositions and methods
EP2360175A3 (en) Norovirus and Sapovirus virus-like particles (VLPs)
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
EP4226938A3 (en) Coronavirus vaccine
DE602004028029D1 (en) Rwendung
Hu et al. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
WO2023147092A3 (en) Coronavirus vaccine
CN103517917A (en) Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells
Li et al. Immunization with a combination of recombinant Brucella abortus proteins induces T helper immune response and confers protection against wild‐type challenge in BALB/c mice
ES2315281T3 (en) RECOMBINANT BCG VACCINES AGAINST INTRACELLULAR PATHOGEN AGENTS AND METHODS OF USE OF THE SAME.
Nandre et al. Construction of a recombinant-attenuated Salmonella Enteritidis strain secreting Escherichia coli heat-labile enterotoxin B subunit protein and its immunogenicity and protection efficacy against salmonellosis in chickens
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
Milan et al. Recombinant protein and DNA vaccines derived from hsp60 Trichophyton mentagrophytes control the clinical course of trichophytosis in bovine species and guinea‐pigs
US8287879B2 (en) Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
Dhiman et al. Immunoprophylactic properties of 71-kDa cell wall-associated protein antigen of Mycobacterium tuberculosis H 37 Ra
MXPA03010053A (en) Saponin inactivated mycoplasma vaccine.
MX2022009549A (en) Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137.
CN106232106A (en) For inducing congenital and adaptive immunity power graininess bacterin preparation
DE60126490D1 (en) ADJUVANE COMPOSITION CONTAINING FHA OR A FHA FRAGMENT IN FREE SHAPE
AU1853995A (en) Vaccine compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21817855

Country of ref document: EP

Kind code of ref document: A2